Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

64.19 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

April 06, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences

April 01, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases

March 24, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma

March 15, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

February 24, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 23, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation

February 21, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation

February 18, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

February 18, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

February 17, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Best Russell 2000 Stocks to Buy Before they Rebound ↗

February 15, 2022

Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.

Via InvestorPlace

Arrowhead Pharmaceuticals's Return On Capital Employed Insights ↗

February 03, 2022

According to data from Benzinga Pro, during Q1, Arrowhead Pharmaceuticals's (NASDAQ:ARWR) reported sales totaled $27.44 million. Despite a 0.79% increase in earnings, the company posted a loss of...

Via Benzinga

The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation ↗

February 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: Arrowhead Pharmaceuticals Q1 Earnings ↗

February 03, 2022

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q1 earnings results on Wednesday, February 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results

February 02, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales ↗

February 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News ↗

January 31, 2022

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.

Via Benzinga

Earnings Scheduled For February 2, 2022 ↗

February 02, 2022

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is likely to report quarterly earnings at $1.57 per share on revenue of $24.59 billion.

Via Benzinga

Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline

January 24, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 First Quarter Results

January 21, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

January 14, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...

Via Benzinga

Arrowhead Pharmaceuticals Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

January 12, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022 ↗

January 19, 2022

Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo...

Via Benzinga

Arrowhead Initiates Project to Build New Manufacturing and Lab Facilities

December 20, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 17, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming December 2021 Conferences

November 30, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug ↗

November 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In...

Via Benzinga

GlaxoSmithKline Pens $1B Pact For NASH Candidate With Arrowhead ↗

November 23, 2021

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) entered a drug development deal with GlaxoSmithKline Plc (NYSE: GSK), under which GSK will develop and market...

Via Benzinga

4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout ↗

November 23, 2021

The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech in line to receive a juicy buyout offer.

Via The Motley Fool

Arrowhead Pharmaceuticals, inc (ARWR) Q4 2021 Earnings Call Transcript ↗

November 22, 2021

ARWR earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.